Cogenics Revenue and Competitors
Estimated Revenue & Valuation
- Cogenics's estimated annual revenue is currently $5M per year.
- Cogenics's estimated revenue per employee is $155,000
Employee Data
- Cogenics has 32 Employees.
- Cogenics grew their employee count by 0% last year.
Cogenics's People
| Name | Title | Email/Phone |
|---|
Cogenics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Cogenics?
Cogenics provides a full range of genomic services for both research and regulated projects, including services to support pharmacogenomics discovery and validation in addition to biomarker research and development. We offer integrated services for DNA and RNA extraction, genotyping, a full range of traditional and next generation sequencing and gene expression. Additional services are offered to support multiple applications of QPCR, cell bank characterization and biorepository/biobanking. Cogenics combines operations from Genaissance, Lark, Icoria, Genome Express, and Epidauros - leveraging over 18 years of genomics experience to deliver superior quality in genomics services. We currently employ around 200 people and operate facilities in Texas, North Carolina, the UK, France, and Germany.
keywords:N/A
N/A
Total Funding
32
Number of Employees
$5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.2M | 32 | -18% | N/A |
#2 | $3.7M | 32 | N/A | N/A |
#3 | $3.7M | 32 | N/A | N/A |
#4 | $6.4M | 32 | N/A | N/A |
#5 | $3.7M | 32 | N/A | N/A |